ibrutinib,zanubrutinib
abbvie,beigene,janssen
['lymsm', 'zanubrutinib', 'leusm', ' ave ', ' ibru']
#ash22 #leusm #lymsm brown: more discontinuations on ibr vs zan. median age 67-68. median prior line of therapy 1. 2yr pfs 79.5% w zan vs 67.3% w ibr. zan favored in all subset analyses. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)